text:
Here's mirroring script that is in place currently:
#!/bin/bash -e
Here's mirroring script that is in place currently:
#!/bin/bash -e
@jukivili was so kind and does the mirroring now.
I just moved Phabricator to a new machine and created separte certificates for files.gnupg.net and dev.gnupg.org.
Thank you for the answer then! You can probably review our guide then https://github.com/ossf/great-mfa-project/blob/main/guide/token-usage-guide.md :)
Thanks for the offer. However, the core developers are using tokens for more than a decade meanwhile. We even make our own tokens ;-).
Since the migration to a new machine with lots of config changes this spring the redirect rules for bugs.gnupg.org were not properly adjusted and when running into an error, it seems that the admin back then ignored the problem and simply removed bugs.gnupg.org from dehydrated's list of domains. Thanks again for reporting. Should now work again.
Right, our installation really needs an update. It is not gnupg.org mail but just the mails from phabricator - which unfortunately does not use our standard mail system
@dkg: Please keep using slashes. The problem was that slashes are not allowed in git config keys. We use the branch name in some git config keys and thus they need to be mapped to soemthing different (ie. '-').
It works for me.
fwiw, i'm used to using slashes in my branch names in dozens of other projects. I was trying to keep my branches scoped under dkg/ so that others could ignore them if they wanted. If the only issue is that i need to not do that, i'm fine naming them with hyphens instead of slashes (or whatever). I'll use that rule for future work.
Just did that: slashes and dots are now mapped to hyphens. Let me know if the problem persists.
That is due to the update hook which has code like this:
That might have been a regression since one of the Phrabricator updates (we need to apply out own patches each time).
Reolved since summer last year.
well, Firefox DE on OSX gives same error Unhandled Exception ("HTTPFutureHTTPResponseStatus")
When did you last try to login to dev.gnupg.org? What browser and OS are you using. Did you try with this account?
I will disable your account but destroying the account and all data is not possible because this has public interlinked content. The intro page at dev.gnupg.org clearly explains this as welll as the privacy policy linked from the side menu; excerpt
close my account
I disabled your account but the I won't delete any comments of yours. They are considered to be in the public domain (see welcome page) and are parts of other bug reports. Thanks for those comments.
For transparency reasons: Intevation will make Werner an offer for maintaining dev.gnupg.org.
The new tool is called txxmpp.
I disabled your account. If might be possible to remove mail addresses from the DB but I don't known how to do that.
Nice code. Need to revisit the jabber protocol to understand what to do.
I am now looking into libstrophe.
No problems, if you get struggled I am here up to go extra mile for an ideal. Regards "convenience" ... well I quite agree with Richard Stallman on the specific topic the trade off between " freedom Vs convenience" https://www.youtube.com/watch?v=CP8CNp-vksc (jump to video @1minutes, 15 seconds) ;-)
We already have a donated machine with everything setup. This is not going to change. Twitter logon is just a convenience for many folks because there are just so many twitter accounts. And after all this is a public tracker.
Hi, Werner what are the machinery requirements required for running the VM ? I can try to squeeze my academic schedule to do it but I probably would like to change twitter login for something more 'GNU' such as https://mastodon.sdf.org/about
Done. Thank you for stopping by.
Retested today: Works again. So I can confirm the resolution of this task.
Thanks @marcus !
No new tools.
The server was replaced due to failure. New IP addresses are: 22.214.171.124 and 2001:678:340::70. I updated the DNS entries, and they seem to have propagated (but your local cache may still refer to the old entries).
Unfortunately, I cannot find a better tool that seems mature, maintained, and packaged for Debian. Maybe it is best to improve the current tool.
Gathered information:
To avoid a single point of failure I would prefer to keep the wiki off from al-kindi and, if Intevation agrees, to keep it where it is.
@marcus you've closed it while I was adding stuff. Where shall we document the way forward? In wiki.gnupg.org or https://dev.gnupg.org/w/ or in this task?
After reviewing the content on the wiki, I don't think anymore that migrating the wiki as a whole is a good strategy, so I will close this simplicistic task. Discussing on the mailing list is of course appropriate.
Note that we could switch the wiki.gnupg.org back to local authentification
(or any other authentification that moinmo.in provides, see https://moinmo.in/AuthMarket)
and continue using it.
Good enough for now.
There are no team encryption keys, that's the problem. So there is at least a dependency between the tasks, as we can't document what we don't have.
I don't see how this duplicates T3074. If the web form is going to encourage people to ask for the team's encryption keys, it should just provide the encryption keys directly.
Well, while this program looks very clean, it is very incomplete, I had to hack it to make starttls work, and I have not been able to send a single message using it :(
I fixed the typo. The actual process is the same as described in https://www.gnupg.org/documentation/bts.html, see also T3074.
@marcus ping
Should be done now.


text:
$6750 Kona Remote 160 DL 2021 Size Large RRP $11,399
The Remote 160 DL is the top-end offering in Kona's five-model line of 2021 aluminum-frame electric mountain bikes, with 160 millimeters of suspension travel front and rear.
This bike has always been shop maintained with new rear triangle bearings, cassette and chain just fitted
Motor - Shimano EP800 with 694kms completed
Battery - Shimano 504Wh
Frame - Kona 6061 Aluminum Butted 160mm Travel
Fork - RockShox Zeb Select + charger RC 2.1 DebonAir 160mm
Shock - RockShox Super Deluxe Select Trunnion
Derailer - SRAM NX-Eagle
Brakeset - SRAM Code R
Wheelset - 29
The bike is located at North Balgowlah, NSW 2093
Independent pre purchase inspections and delivery options are available at buyer expense.
This bike is advertised on behalf of the owner by Trails View Cycle Trader

subset: commoncrawl


text:
Terms and Conditions
Privacy Policy
Agoyu provides moving estimates and the ability for a consumer to create a moving profile which moving companies can bid on your move. We hold true to our core values, and our mission is our commitment to upholding the highest standards of data protection for our consumers.
This Privacy Policy applies to the Agoyu Site which link to this policy and are published on our site here. If you have additional questions about how we use your personal information, please contact our team at [email protected].
Information We Collect.
This section details the information we may collect about you. We explain why and how we use your information in the following ways:
Account information
Information Agoyu obtains from partners and public sources
Log in information such as username and password
Payment details (only when specified in the marketplace)
Information Agoyu obtains from partners and public sources
In some cases, Agoyu will collect information about your from our partners or from publicly available websites to help us understand our audience and enhance the relevance of our content.
Information we obtain through cookies and similar tools:
We use cookies and analytics tools across our Site to collect information about you. This information can be used to improve the performance of our site, make advertising more relevant to you and enhance your user experience. We provide all the information about cookies and similar technologies within our Cookie Policy.
How we use your personal information.
Account information
To provide the Agoyu service. We require some of your basic personal information so our services work as you would expect. For example, telling a moving company where to go to move your household goods.
To improve and maintain performance of our website. In order for Agoyu to provide you with the best possible user experience, we need to make sure our product and services work as they should. Using personal information helps us understand how our consumers use our Site so we can make improvements. This includes testing proposed new developments on our Site.
For billing. If you're a company user, and your access is permissioned from your employer under a group subscription, we use cookies for the purposes of measuring activity and billing
To monitor compliance with our policies and terms. Agoyu monitors for breaches of our terms, conditions and copyright policies.
To personalize our products and services. Agoyu improves your user experience of our product and services by personalizing parts of our Site with the information you give us and learn about you. This includes showing you advertisements you may be interest in, and recommending service providers you may want to use.
To communicate product changes and offers. Agoyu wants you to get the most out of our product. We will contact you with carefully curated offers, promotions and feature announcements.
For the purpose of advertising. Agoyu relies on advertising revenue in part to support our platform. We need to process your information to understand the effectiveness of the advertising we serve you and others to deliver relevant ads.
Who we share your personal information with.
We disclose personal information to facilitate the running of our business or to provide services your have specifically requested. Commonly we will disclose this information to service providers and advertisers to help support our business and improve our products.
How we keep your information secure.
Agoyu has the appropriate technical (encryption) and administrative security measures in place to prevent against unauthorized or accidental access, use, alteration or loss of your information.
Agoyu uses cookies to keep our site reliable, secure and personalized to you. When you accept our cookie policy, this helps us make the site better by remembering your preferences, past searches, and customize content and ads. This Cookie Policy applies to all web applications which link to this policy and are published by Agoyu companies. This policy should be read alongside our Privacy Policy, which explains how we use your personal information.
If you have any questions about the way we use your personal information or cookies, please contact our team at [email protected].
If you wish to manage your cookies, please follow the instructions in the "How to manage your cookies" section below.
What are cookies?
Cookies are small text files which a website may place on your computer or device when you visit a site. At this point you should be aware, most websites and applications you visit use cookies. The cookie will help our website, and any other website that uses them, recognize your device the next time you visit. Web beacons, pixels or other similar files can also do the same thing. Agoyu uses the term "cookies" in our policy to refer to all files that collect information in this way.
Cookies serve many functions. For example:
- They help us to remember your username and preferences
- Analyze how well our Sites are performing
- Allow us to recommend content we believe is relevant to you
The majority of websites on the internet use cookies to collect and retain personal information about their users. Most cookies collect general information such as how visitors arrive at and use our site, the device they are using, their internet protocol address (IP address), what pages they are viewing and the users approximate location.
The purpose of cookies
Operating our site, we group cookies into the following categories:
- Access – Agoyu uses cookies to identify subscribers and general users to ensure access to permissioned-based content, including subscription-based access
- Billing – if you're a company user, and your access is permissioned from your employer under a group subscription, we use cookies for the purposes of measuring activity and billing
- Performance – Agoyu uses cookies to monitor Site performance. This allows us to provide a high quality experience by quickly identifying and fixing issues that arise on the fly. For example, Agoyu uses cookies to track error messages, and determine fixes that will improve our site
- Functionality – Agoyu uses functional cookies to allow us to remember your preferences. For example we can provide you with relevant ads, or location specific recommendations for moving companies, or realtors
- Analytics – Agoyu uses cookies to help us understand our audience and the success of advertising campaigns. For example – we count the number of users who specify their moving destination in a specific location. This allows us to keep track of how many advertising impressions have been served for a ad campaign and to manage the frequency at which you see the same advertisements
- Fraud prevention – we use cookies to monitor and prevent suspicious activity and fraudulent traffic on our site
Personalization and advertising
Agoyu uses cookies to improve your user experience of our product by personalizing our Site. We also use cookies to present you with advertisements on our Site. For example, if you visit a number of sites on moving boxes, you would see more moving box advertisements as we have inferred that you are interested in the product. You may also see advertisements for other products and services on other websites if you have previously visited our Site.
On our site, there are behavioral and demographically targeted advertisements. You have the ability to turn this off in your account. Please note however, you will still see the same number of ads, they will just be less relevant to you. You may still see "contextual" advertisements that are not targeted based on your personal information, but based on the relevance of the page or service you are requesting.
Third party cookies and their use on our site
We also use third-party cookies on our Site that fall into the following categories for the following reasons:
- To help Agoyu monitor traffic on our Site (like a majority of websites, we use Google Analytics to do this)
- To help Agoyu identify fraudulent or non-human traffic
- To assist Agoyu with market research
- To help Agoyu improve Site functionality
- To help Agoyu monitor compliance with our terms and conditions and copyright policy
These third-party cookies may also be used for personalization of advertisements based on the data you have shared with third parties, to the extent you have consented to this.
Use of pixels in emails
Agoyu's emails often contain a campaign unique "web beacon pixel" to tell us whether, and how many times our emails are opened and verify any clicks through to links or advertisements within our email. We use this information to determine which of our emails are more interesting to our users. This helps us report back to advertisers on our users activity and engage with their products or services.
More information
Further information about our data processing can be found in our Privacy Policy. If you have any questions regarding Agoyu's Cookie Policy, please contact our team at [email protected]
Manage your cookies
You can manage which cookies are set on your device, but if you disable some cookies, some parts of the Agoyu Site will not work properly. Some cookies are essential for the operation of the Agoyu Site. Please refer to our Cookie Policy for more information on this.
To turn off all cookies used by Agoyu for personalized advertising you will need to follow steps 1 and 2 in your browser settings.
Step 1: Advertisements based on your use of the Agoyu Site
Agoyu helps you see advertisements with products and services that are relevant to you, based on your characteristics, your online activity and your interests.
If you turn this off, you will still see the same number of advertisements but they may be less relevant to you. You may also continue to see advertisements that are targeted to you based on other information.
Step 2: Advertisements based on your online activity
Agoyu uses third party cookies on our Site to serve you with advertisements that we believe are relevant to you and your interests. You may see these advertisements on our Site and on other sites that you visit. You can opt out of our use of these cookies in your browser settings.
Agoyu Platform Terms of Use
Last Updated: September 1, 2020
This Terms of Use Agreement ("Terms"), including the BINDING ARBITRATION AND CLASS ACTION WAIVER CONTAINED HEREIN govern your access to, use of, and participation in the Platform made available by Agoyu, LLC, a Puerto Rico limited liability company ("Agoyu," "we," "our," or "us") or through Agoyu and the entirety of your relationship with Agoyu.
All references to "you" or "your," as applicable, mean the person who accesses, uses, and/or participates in the Platform in any manner, and each of your heirs, assigns, and successors. If you use the Platform on behalf of an entity, you represent and warrant that you have the authority to bind that entity, your acceptance of the Terms will be deemed an acceptance by that entity, and "you" and "your" herein shall refer to that entity, its directors, officers, employees, and agents.
If you have any questions about these Terms or the Platform, please contact us by sending an email to [email protected], or by writing to Agoyu, Inc., at 11350 Random Hills Road Suite 130 Fairfax, VA 22030, ATTN: Agoyu Legal.
"Collective Content" means User Content and Agoyu Content together.
"Content" means text, graphics, images, music, software, audio, video, information or other materials, including but not limited to profile information, service requests, quotes, message threads, reviews, scheduling and calendar information, and other information or materials available on or through the Platform.
"Consumer User" means a User who is registered to receive quotes for Moving Services, requests quotes for Moving Services, or otherwise uses the Platform to receive, pay for, review, or facilitate the receipt of Moving Services.
"User" means a person or entity who completes Agoyu's account registration process or a person or entity who submits or receives a request through Agoyu.
"Platform" means all Agoyu websites, mobile or other applications, software, processes and any other services provided by or through Agoyu.
"Moving Services" means the moving and related services listed, quoted, scheduled, offered or provided by Service Users, or sought, scheduled or received by Consumer Users, through the Platform.
"Service User" means a User who is registered to send quotes for Moving Services, sends quotes for Moving Services, or otherwise uses the Platform to offer, provide, receive payment for, or facilitate the provision of Moving Services.
"Agoyu Content" means all Content Agoyu makes available on or through the Platform, including any Content licensed from a third party, but excluding User Content.
"User Content" means all Content submitted, posted, uploaded, published, or transmitted on or through the Platform by any User or other user of the Platform, including but not limited to photographs, profile information, descriptions, postings, reviews, requests, messages, and payments made through the Platform, but excluding Agoyu Content and Feedback.
Agoyu is not an agent of either you or any Service Provider. Agoyu's services are only offering a technology platform. You agree you will rely on your own judgment and research independent of any communications or information you receive from Agoyu in deciding which available product, terms and Service Provider best suits your needs and financial situation.
Subject to your compliance with these Terms, Agoyu grants you a limited, non-exclusive, revocable, nontransferable, and non-sublicensable license to reproduce and display Collective Content (excluding any software source code) solely for your personal and non-commercial use and only in connection with your access to and participation in the Platform. You will not use, copy, adapt, modify, prepare derivative works based upon, distribute, license, sell, transfer, publicly display, publicly perform, transmit, stream, broadcast or otherwise exploit the Platform or Collective Content, except as expressly permitted in these Terms. The Platform and Collective Content are provided to you AS IS. If you download or print a copy of Collective Content for personal use, you must retain all copyright and other proprietary notices contained thereon. No licenses or rights are granted to you by implication or otherwise under any intellectual property rights owned or controlled by Agoyu or its licensors, except for the licenses and rights expressly granted in these Terms.
Agoyu Content is protected by copyright, trademark, and other laws of the United States, foreign countries, and international conventions. Except as expressly provided in these Terms, Agoyu and its licensors exclusively own all right, title, and interest in and to the Platform and Agoyu Content, including all associated intellectual property rights. All trademarks, service marks, logos, trade names and any other proprietary designations of Agoyu used herein are trademarks or registered trademarks of Agoyu. Any other trademarks, service marks, logos, trade names and any other proprietary designations are the trademarks or registered trademarks of their respective owners. You acknowledge and agree that the Platform is provided under license, and not sold, to you. You do not acquire any ownership interest in the Platform under these Terms, or any other rights thereto other than to use the Platform in accordance with the license granted, and subject to all terms, conditions, and restrictions, under this Terms. Agoyu reserves and shall retain its entire right, title, and interest in and to the Platform, including all copyrights, trademarks, and other intellectual property rights therein or relating thereto, except as expressly granted to you in this Terms.
These Terms govern your use of the Agoyu Mobile Application (the "Application"). The Application is part of the Agoyu Platform. The Application is licensed, not sold, to you. You may download, install, and use the Platform's Application for your personal, non-commercial use on a single mobile device owned or otherwise controlled by you strictly in accordance with the Application's documentation The Application is commercial computer software, as such term is defined in 48 C.F.R. §2.101. Accordingly, if you are an agency of the U.S. Government or any contractor therefor, you receive only those rights with respect to the Application as are granted to all other end users under license, in accordance with (a) 48 C.F.R. §227.7201 through 48 C.F.R. §227.7204, with respect to the Department of Defense and their contractors, or (b) 48 C.F.R. §12.212, with respect to all other US Government licensees and their contractors.
Agoyu may from time to time in its sole discretion develop and provide Application updates, which may include upgrades, bug fixes, patches, other error corrections, and/or new features (collectively, including related documentation, "Updates"). Updates may also modify or delete in their entirety certain features and functionality. You agree that Agoyu has no obligation to provide any Updates or to continue to provide or enable any particular features or functionality. Based on your mobile device settings, when your mobile device is connected to the internet either:
- – The Application will automatically download and install all available Updates;
- – You may receive notice of or be prompted to download and install available Updates.
You shall promptly download and install all Updates and acknowledge and agree that the Application or portions thereof may not properly operate should you fail to do so. You further agree that all Updates will be deemed part of the Application and be subject to all terms and conditions of this Agreement.
Please review Agoyu's Platform Privacy Policy, incorporated herein by reference, for information and notices concerning Agoyu's collection and use of your information. The provision and delivery of text messages by Agoyu or our text message service providers is governed by the applicable portions of these Terms, which are expressly incorporated herein. Please review the full set of key Agoyu policies that govern your use of the Platform and our interactions with you and third parties. Certain areas of and/or products on the Platform may have different terms and conditions posted or may require you to agree with and accept additional terms and conditions or policies. If there is a conflict between these Terms and the terms and conditions or policies posted for a specific area or product, the latter take precedence with respect to your use of that area or product.
Agoyu is compensated by Service Users for use of the Platform and may be paid a marketing lead generation fee by Service Users for the goods, facilities and services provided. Agoyu may modify its compensation structure without notice to you. Your use of the Platform and/or Agoyu's services constitutes your agreement with Agoyu's compensation arrangements.
Your use of the platform, moving services, or collective content shall be solely at your own risk. You acknowledge and agree that agoyu does not have an obligation, but reserves the right for any reason, to (a) monitor or review user content; or (b) for any permissible purpose, conduct identity verification and other background checks, including but not limited to service users and consumer users. The platform is provided "As is," without warranty of any kind, either express or implied. Without limiting the foregoing, agoyu and its affiliates and subsidiaries, and their respective officers, directors, employees and agents explicitly disclaim any warranties of merchantability, fitness for a particular purpose, quiet enjoyment or non-infringement; any warranties arising out of course of dealing or usage of or in trade; any warranties, representations, or guarantees in connection with this platform or the moving services offered on or through this platform; and any warranties relating to the quality, suitability, truth, accuracy or completeness of any information or material contained or presented on the platform, including without limitation all collective content. Agoyu makes no warranty that the platform or moving services will meet your requirements or be available on an uninterrupted, secure, or error-free basis. Agoyu assumes no responsibility, and shall not be liable for any damages to your computer equipment or other property on account of your access to or use of the platform. Agoyu shall not be liable for any defamatory, offensive, or illegal conduct of any third party, or any loss or damage of any kind incurred as a result of the use of any data, information, materials, substance, or collective content posted, transmitted, or made available via the platform. No advice or information, whether oral or written, obtained from agoyu or through the platform, will create any warranty not expressly made here in.
You are solely responsible for all of your communications and interactions with other users or users of the platform and with other persons with whom you communicate or interact as a result of your use of the platform, including but not limited to any consumer users, service users or service recipients. You understand that agoyu does not make any attempt to verify the statements of users of the platform or to review or vet any moving services or service users. Agoyu makes no representations or warranties as to the conduct of users of the platform or their compatibility with any current or future users of the platform. You agree to take reasonable precautions in all communications and interactions with other users of the platform and with other persons with whom you communicate or interact as a result of your use of the platform, particularly if you decide to meet offline or in person and give or receive moving services. Agoyu explicitly disclaims all liability for any act or omission of any users or third parties.
Agoyu is not responsible for any errors or delays in responding to a request or referral form caused by, including but not limited to, an incorrect email address or other information provided by you or other technical problems beyond our reasonable control.
Access to and use of the Platform is available only to individuals who are at least 18 years old and can form legally binding contracts under applicable law. By accessing or using the Platform, you represent and warrant that you are eligible.
You understand that Agoyu is not in the business of providing Moving Services and that Moving Services are provided by Service Users. Agoyu is not responsible for the Moving Services provided by the Service Users, the quality of the Moving Services, your household or other goods, or any damages that you or others might incur as a result of obtaining Moving Services from a Service User.
Users may access the Platform without registering for an account. To access and participate in certain features of the Platform, you will need to create a password-protected account ("Account"). We may allow you to register for an Account using certain third-party account and log-in credentials (your "Third-Party Site Password"), such as your Facebook or Google credentials. You agree to provide accurate, current, and complete information during the registration or request submission process and at all other times when you use the Platform, and to update information to keep it accurate, current, and complete. You are solely responsible for safeguarding your Agoyu password and, if applicable, your Third-Party Site Password. You are solely responsible for all activity that occurs on your Account, and you will notify Agoyu immediately of any unauthorized use. Agoyu is not liable for any losses by any party caused by an unauthorized use of your Account. Notwithstanding the foregoing, you may be liable for the losses of Agoyu or others due to such unauthorized use. Your account is nontransferable except with Agoyu's written permission and in line with Agoyu policies and procedures.
By using this Platform and submitting a request for a quote for Moving Services (a "submission"), you indicate your desire to be connected with a Service Provider, you understand that you are agreeing to the stated terms and conditions of that submission and that you are submitting an inquiry to Agoyu and its network of Service Providers. You authorize Agoyu to forward your information to the Service Providers. You further understand and agree that by selecting a Service Provider or other provider, you are providing express written consent for them to contact you by telephone at the numbers (whether landline or cellular) you have provided, including for marketing purposes, and you hereby consent to any such calls even if your phone number is on the Do Not Call list. You consent to receive email from Agoyu, its affiliates, and its Service Providers at the email address you provided or at other addresses that may be associated with you that we receive from Service Providers or other parties. You hereby consent to any such email, so it will not be considered spam or unauthorized by any local, state or federal law or regulation. You agree that the consents described herein shall remain valid and in effect until you revoke them by opting out. You are providing express written consent that Agoyu, a third party on Agoyu's behalf, and Service Providers with whom you are matched, may deliver calls or text messages to you, including for marketing purposes, using an automatic telephone dialing system or an artificial or prerecorded voice to the phone number you have provided. You understand that you are not required to consent to receive these communications as a condition of using Agoyu's services.
These terms govern the provision and delivery of text messages by us or our text message service providers to you. Agoyu may provide this service to our users. We or our service providers may send text messages to: (1) provide you with information you requested from Agoyu; (2) inform you of improvements, features, or Agoyu services that may be of interest to you; (3) to facilitate the matching of Agoyu users with movers or other features you voluntarily use on Agoyu; and (4) to respond to your inquiries regarding your account or use of Agoyu.
You may sign up to receive text messages through our Platform. By signing up to receive text messages, you agree to these SMS Terms and the Terms. By signing up to receive Agoyu text messages, you agree that Agoyu or its agents may use any automated or non-automated technology to send you informational and/or promotional text messages. The types of text messages you will receive depend on the SMS campaign(s) you opt into. You understand that you are not required to receive Agoyu text messages as a condition of using the Platform.
Agoyu does not charge you for its text message program. But message and data rates may apply, so depending on your plan with your wireless or other applicable provider, you may be charged by your carrier or other applicable provider. We may send you an initial message confirming that we have received your opt-in. After that, you will receive recurring text messages, and the specific amount may vary depending on how you use our Platform.
The number of text messages you receive may depend upon factors including how you use our services and whether you take steps to generate additional text messages from us. By signing up to receive Agoyu text messages, you represent that you are 18 years of age or older and understand the obligations and agree to the terms set forth in these Terms which form a binding agreement between you and us. You further represent that you are the subscriber of the cellular service at the mobile number provided or that you are authorized by the subscriber to sign-up for texts. If you no longer want to receive Agoyu text messages, you may opt-out. After doing so, we will send you confirmation of your opt-out via text message. If you have revoked consent and want to re-enroll in our text message program, you can re-enroll through our website.
In some instances, Agoyu may choose to track the occurrence of communications between Consumer Users and Service Users that occur off of the Platform via email, phone call, SMS text message, third-party websites, or any other means, whether initiated by a Consumer User or Service User. In order to track the occurrence of such communications, Agoyu may obscure Service User contact information in a Service User profile, replace Service User contact information in a Service User profile with a different piece of contact information that will forward to the Service User, or take any other step reasonably calculated to track the occurrence of such communications. Except as explicitly stated herein, we will not record or review the content of any communications that do not come into contact with the Agoyu Platform unless we first obtain your permission.
If you send text messages with a Consumer User or Service User using the telephone number for that User available on the Platform, we may use a third-party service provider to track these text messages. We may track these text messages for fraud prevention, to enforce these Terms, and for quality and training purposes. As part of this process, Agoyu and its service provider may receive in real time and store data about your text message, including the date and time of the text message, your phone number, and the content of the text message.
Agoyu may publicly display advertisements, paid content, and other sponsored information. The manner, mode, and extent of such advertising are subject to change without specific notice to you. Service Users may compensate Agoyu to promote themselves in search results and therefore rank higher.
As a user of the Platform, you may not:
- Use another person's Account, misrepresent yourself or Moving Services offered through the Platform, misrepresent your identity or qualifications, misrepresent information in a quote request, or post Content in any inappropriate category or areas on the Platform;
- Use any automated system including but not limited to robots, spiders, offline readers, or scrapers to access the Platform for any purpose without Agoyu's prior written approval; provided, however, that the operators of public search engines may use spiders or robots to copy materials from the Platform for the sole purpose of creating publicly available searchable indices of the materials, but not caches or archives of such material (Agoyu reserves the right to revoke these exceptions either generally or in specific cases);
- In any manual or automated manner copy copyrighted text, or otherwise misuse or misappropriate Platform information or Content including but not limited to, for use on a mirrored, competitive, or third-party site;
- Transmit more request messages through the Platform in a given period of time than a human can reasonably produce in the same period by using a conventional online web browser;
- Take any action that (a) may unreasonably encumber the Platform's infrastructure; (b) interferes or attempts to interfere with the proper working of the Platform or any third-party participation; (c) bypasses measures that are used to prevent or restrict access to the Platform; (d) circumvents, disables or otherwise interferes with security features of the Platform; (e) distributes viruses or any other technologies that may harm Agoyu or users; (f) uses the Platform in a way that violates any copyrights, trade secrets, or other rights of any third party, including privacy or publicity rights; or (g) circumvents or manipulates any fees owed to Agoyu or a Service User;
- As a Service User, use the Platform in any manner that circumvents your obligation to pay Agoyu for access to services provided by the Platform;
- As a Service User, violate any other agreements you may have with Agoyu;
- Collect, harvest, or publish any personally identifiable data including but not limited to names or other account information, from the Platform, or use the communication systems provided by the Platform for any reason not explicitly authorized by these Terms, including commercial solicitation purposes;
- Take any inappropriate or unlawful actions, including the submission of inappropriate or unlawful Content to or through the Platform, including Content that is harassing, hateful, illegal, profane, obscene, defamatory, threatening, or discriminatory, or that advocates, promotes, or encourages inappropriate activity, conduct that would be considered a criminal offense, or conduct that would give rise to civil liability or violate any law;
- Submit User Content that damages the experience of any user including but not limited to (a) requests to download non-Agoyu mobile applications and/or links that direct the user to mirrored websites where the user must enter information that is redundant with what has already been entered on Agoyu, (b) offers to purchase a Moving Service or any other service outside of Agoyu, or (c) using a profile page or user name to promote services not offered on or through the Platform;
- Take any action that may undermine the efficacy or accuracy of reviews or ratings systems;
- Sign up for, negotiate a price for, use, or otherwise solicit a Moving Service with no intention of following through with your use of or payment for the Moving Service;
- Agree to purchase a Moving Service when you do not meet a Service User's requirements;
- Undertake any activity or engage in any conduct that is inconsistent with the business or purpose of the Platform; and
- Attempt to indirectly undertake any of the foregoing.
- copy the Platform, except as expressly permitted by this license;
- modify, translate, adapt, or otherwise create derivative works or improvements, whether or not patentable, of the Platform;
- reverse engineer, disassemble, decompile, decode, or otherwise attempt to derive or gain access to the source code of the Platform or any part thereof;
- remove, delete, alter, or obscure any trademarks or any copyright, trademark, patent, or other intellectual property or proprietary rights notices from the Platform, including any copy thereof;
- rent, lease, lend, sell, sublicense, assign, distribute, publish, transfer, or otherwise make available the Platform, or any features or functionality of the Platform, to any third party for any reason, including by making the Platform available on a network where it is capable of being accessed by more than one device at any time; or
- remove, disable, circumvent, or otherwise create or implement any workaround to any copy protection, rights management, or security features in or protecting the Platform.
We may, in our sole discretion, permit you to post, upload, publish, submit or transmit User Content. By making available any User Content on or through the Platform, you hereby grant to Agoyu a worldwide, irrevocable, perpetual, non-exclusive, transferable, royalty-free license, with the right to sublicense, to use, copy, adapt, modify, distribute, license, sell, transfer, publicly display, publicly perform, transmit, stream, broadcast, access, view, and otherwise exploit such User Content on, through, by means of or to promote, market or advertise the Platform or Moving Services, or for any other purpose in our sole discretion, except that the contents of private messaging through the Platform will not be used by Agoyu in public advertising. In the interest of clarity, the license granted to Agoyu shall survive termination of the Platform or your Account. Agoyu does not claim ownership rights in your User Content and nothing in these Terms will be deemed to restrict rights that you may have to use and exploit any such User Content submitted, posted, uploaded, published, or transmitted on or through the Platform by you.
You acknowledge and agree that you are solely responsible for all User Content that you make available on or through the Platform. Accordingly, you represent and warrant that: (a) you either are the sole and exclusive owner of all User Content that you make available on or through the Platform or you have all rights, licenses, consents and releases that are necessary to grant to Agoyu the rights in such User Content, as contemplated under these Terms; and (b) neither the User Content nor your posting, uploading, publication, submission or transmittal of the User Content or Agoyu's use of your User Content (or any portion thereof) on, through or by means of the Platform will infringe, misappropriate or violate a third party's patent, copyright, trademark, trade secret, moral rights or other proprietary or intellectual property rights, or rights of publicity or privacy, or result in the violation of any applicable law or regulation. While it has no obligation to do so, you agree that Agoyu may proofread, summarize or otherwise edit and/or withdraw your User Content, and you understand it remains your sole responsibility to monitor your User Content and ensure that such edited Content is accurate and consistent with your representations and warranties in these Terms.
Agoyu reserves the right, at any time and without prior notice, to remove or disable access to User Content that we, in our sole discretion, consider to be objectionable for any reason, in violation of these Terms or otherwise harmful to the Platform or users, or for any other reason.
Agoyu values our Service Users and Consumer Users, and we understand that occasionally disputes may arise between or among them. Our goal is to provide tools to help users resolve such disputes independently. In the rare event a dispute regarding an interaction related to the Platform cannot be resolved independently, you agree, at Agoyu's request, to participate in good faith, to the extent you are reasonably able to do so, in a neutral resolution or mediation conducted by Agoyu or a neutral third-party mediator or arbitrator selected by Agoyu. Notwithstanding the foregoing, you acknowledge and agree that Agoyu is under no obligation to become involved in or impose resolution in any dispute between or among users or any third party.
By sending us any feedback, comments, questions, or suggestions concerning Agoyu or our services, including the Platform (collectively, "Feedback") you represent and warrant (a) that you have the right to disclose the Feedback, (b) that the Feedback does not violate the rights of any other person or entity, and (c) that your Feedback does not contain the confidential or proprietary information of any third party or parties. By sending us any Feedback, you further (i) agree that we are under no obligation of confidentiality, express or implied, with respect to the Feedback, (ii) grant us an irrevocable, non-exclusive, royalty-free, perpetual, worldwide license to use, modify, prepare derivative works, publish, distribute and sublicense the Feedback, and (iii) irrevocably waive, and cause to be waived, against Agoyu and its users any claims and assertions of any moral rights contained in such Feedback. This Feedback section shall survive any termination of your Account or the Platform.
We expect Users to respect copyright law. In appropriate circumstances we will terminate the Account of any user who repeatedly infringes or is believed to be repeatedly infringing the rights of copyright holders.
The Platform may be subject to U.S. export control laws, including the Export Control Reform Act and its associated regulations. You shall not, directly or indirectly, export, re-export, or release the Platform to, or make the Platform accessible from, any jurisdiction or country to which export, re-export, or release is prohibited by law, rule, or regulation. You shall comply with all applicable federal laws, regulations, and rules, and complete all required undertakings (including obtaining any necessary export license or other governmental approval), prior to exporting, re-exporting, releasing, or otherwise making the Platform available outside the U.S.
Agoyu does not endorse any User, user, or any Service User, and Agoyu is not a party to any agreements between or among users, Users, or third parties. No agency, partnership, joint venture, or employment is created as a result of the Terms or any user's or User's use of any part of the Platform, including but not limited to any estimating, scheduling or other services. Neither Agoyu nor any Users or users of the Platform may direct or control the day-to-day activities of the other, or create or assume any obligation on behalf of the other. Users are required by these Terms to provide accurate information, and although Agoyu may undertake additional checks and processes designed to help verify or check the identities or backgrounds of users, we do not make any representations about, confirm, or endorse any user or their purported identity or background, regardless of the specific Agoyu services they are using or any involvement by Agoyu personnel in providing or scheduling those services.
Any reference on the Platform to a user being licensed or credentialed in some manner, indicates only that the user has completed a relevant account process or met user review standards, and does not represent anything else. Any such description is not an endorsement, certification or guarantee by Agoyu and is not verification of their identity and whether they or their Moving Services are licensed, insured, trustworthy, safe or suitable. Instead, any such description is intended to be useful information for you to evaluate when you make your own decisions about the identity and suitability of others whom you contact or interact with via the Platform. You should always exercise responsibility, due diligence and care when deciding whether to have any interaction with any other user. Except as specifically described in the Agoyu Guarantee and including its exclusions and limitations, Agoyu has no responsibility for any damage or harm resulting from for your interactions with other users.
The Collective Content may contain links to third-party websites, offers, or other events/activities not owned or controlled by Agoyu. We do not endorse or assume any responsibility for any such links, and if you access them, you do so at your own risk.
By using the Platform, you understand and agree that any legal remedy or liability that you seek to obtain for actions or omissions of other users or other third parties will be limited to a claim against those particular users or other third parties. You agree not to attempt to impose liability on or seek any legal remedy from Agoyu with respect to such actions or omissions.
Without limiting any other rights reserved herein, Agoyu may, in its sole discretion, take any action permitted by law for any violation of these Terms or any other policy or agreement between you and Agoyu, including but not limited to removing User Content you posted, limiting your Account access, requiring you to forfeit certain funds or paid Fees, assessing monetary penalties or costs, terminating your Account, notifying other Users of the termination of your Account and/or the violation of these Terms, decreasing your status or search rank, canceling quotes or postings, blocking access, investigating you, and/or cooperating with law enforcement agencies in investigation or prosecution.
We may, in our discretion, with or without cause, with or without prior notice and at any time, decide to limit, block, suspend, deactivate or cancel your Agoyu Account in whole or in part. If we exercise our discretion under these Terms to do so, any or all of the following can occur with or without prior notice or explanation to you: (a) your Account will be deactivated or suspended, your password will be disabled, and you will not be able to access the Platform or your User Content, or receive assistance from Agoyu support teams; (b) if appropriate in our sole discretion, we may communicate to other users that your Account has been terminated, blocked, suspended, deactivated, cancelled, or otherwise penalized in any way, and why this action has been taken. You may cancel your use of the Platform and/or terminate your Account at any time. Please note that if your Account is cancelled, we do not have an obligation to delete or return to you any Content you have posted to the Platform, including, but not limited to, any reviews.
You and Agoyu agree that these Terms affect interstate commerce and that the Federal Arbitration Act governs the interpretation and enforcement of these arbitration provisions.
This Section is intended to be interpreted broadly and governs any and all disputes between us, including but not limited to claims arising out of or relating to any aspect of the relationship between us, whether based in contract, tort, statute, fraud, misrepresentation or any other legal theory; claims that arose before this Agreement or any prior agreement (including, but not limited to, claims related to advertising); and claims that may arise after the termination of this Agreement. The only disputes excluded from this broad prohibition are the litigation of certain intellectual property and small court claims, as provided below.
By agreeing to these Terms, you agree to resolve any and all disputes with Agoyu as follows:
Initial Dispute Resolution: Most disputes can be resolved without resort to litigation. You can reach Agoyu's support department at [email protected]. Except for intellectual property and small claims court claims, the parties agree to use their best efforts to settle any dispute, claim, question, or disagreement directly through consultation with the Agoyu support department, and good faith negotiations shall be a condition to either party initiating a lawsuit or arbitration.
Binding Arbitration: If the parties do not reach an agreed-upon solution within a period of thirty (30) days from the time informal dispute resolution is initiated under the Initial Dispute Resolution provision above, then either party may initiate binding arbitration as the sole means to resolve claims, subject to the terms set forth below. Specifically, all claims arising out of or relating to these Terms or previous versions of these Terms (including the Terms' or Privacy Policy's formation, performance, and breach), the parties' relationship with each other, and/or your use of the Platform shall be finally settled by binding arbitration, as described below.
Where the relief sought is $10,000 or less and you do not wish to bring the claim in small claims court, the arbitration will be conducted online by an online arbitration provider of our choosing in accordance with their applicable Arbitration Rules & Procedures effective at the time a claim is made. You are responsible for your own attorneys' fees unless the arbitration rules and/or applicable law provide otherwise.
Where the relief sought is $10,001 or more, resolution shall be in accordance with the JAMS Streamlined Arbitration Procedure Rules for claims that do not exceed $250,000 and the JAMS Comprehensive Arbitration Rules and Procedures for claims exceeding $250,000 in effect at the time the arbitration is initiated, excluding any rules or procedures governing or permitting class actions. To start an arbitration with JAMS, you must do the following: (a) write a Demand for Arbitration that includes a description of the claim and the amount of damages you seek to recover (you may find a copy of a Demand for Arbitration at www.jamsadr.com); (b) send three copies of the Demand for Arbitration, plus the appropriate filing fee, to JAMS, Two Embarcadero Center, Suite 1500, San Francisco, California 94111; and (c) send one copy of the Demand for Arbitration to Agoyu at 11350 Random Hills Road Suite 130 Fairfax, VA 22030, ATTN: Agoyu Legal. You will be required to pay $250 to initiate an arbitration against us. If the arbitrator finds the arbitration to be non-frivolous, Agoyu will pay all other fees invoiced by JAMS, including filing fees and arbitrator and hearing expenses. You are responsible for your own attorneys' fees unless the arbitration rules and/or applicable law provide otherwise.
The arbitrator, and not any federal, state, or local court or agency, shall have exclusive authority to resolve all disputes arising out of or relating to the interpretation, applicability, enforceability, or formation of these Terms or the Privacy Policy, including but not limited to any claim that all or any part of these Terms or Privacy Policy is void or voidable, whether a claim is subject to arbitration, or the question of waiver by litigation conduct. The arbitrator shall be empowered to grant whatever relief would be available in a court under law or in equity. The arbitrator's award shall be written and shall be binding on the parties and may be entered as a judgment in any court of competent jurisdiction.
The parties understand that, absent this mandatory arbitration provision, they would have the right to sue in court and have a jury trial. They further understand that, in some instances, the costs of arbitration could exceed the costs of litigation and the right to discovery may be more limited in arbitration than in court.
Arbitration shall be initiated in the Commonwealth of Virginia, United States of America. You and Agoyu further agree to submit to the personal jurisdiction of any federal or state court in or for Fairfax County, Virginia in order to compel arbitration, to stay proceedings pending arbitration, or to confirm, modify, vacate, or enter judgment on the award entered by the arbitrator.
Class Action Waiver: The parties further agree that the arbitration shall be conducted in their individual capacities only and not as a class action or other representative action, and the parties expressly waive their right to file a class action or seek relief on a class basis. YOU AND AGOYU AGREE THAT EACH MAY BRING CLAIMS AGAINST THE OTHER ONLY IN YOUR OR ITS INDIVIDUAL CAPACITY, AND NOT AS A PLAINTIFF OR CLASS USER IN ANY PURPORTED CLASS OR REPRESENTATIVE PROCEEDING. If any court or arbitrator determines that the class action waiver set forth in this paragraph is void or unenforceable for any reason or that an arbitration can proceed on a class basis, then the arbitration provisions set forth above shall be deemed null and void in their entirety and the parties shall be deemed to have not agreed to arbitrate disputes.
Exception: Litigation of Intellectual Property and Small Claims Court Claims: Notwithstanding the parties' decision to resolve all disputes through arbitration, either party may bring enforcement actions, validity determinations or claims arising from or relating to theft, piracy or unauthorized use of intellectual property in state or federal court or in the U.S. Patent and Trademark Office to protect its intellectual property rights ("intellectual property rights" means patents, copyrights, moral rights, trademarks, and trade secrets, but not privacy or publicity rights). Either party may also seek relief in a small claims court for disputes or claims within the scope of that court's jurisdiction.
30-Day Right to Opt Out: You have the right to opt out and not be bound by the arbitration and class action waiver provisions set forth above by sending (from the email address you use on Agoyu) written notice of your decision to opt out to [email protected] with the subject line, "ARBITRATION AND CLASS ACTION WAIVER OPT-OUT." The notice must be sent within thirty (30) days of the later of the Effective Date of these Terms or your first use of the Platform; otherwise, you shall be bound to arbitrate disputes in accordance with the terms of those paragraphs. If you opt out of these arbitration provisions, Agoyu also will not be bound by them.
Changes to This Section: Agoyu will provide thirty (30) days' notice of any changes affecting the substance of this Arbitration and Class Action Waiver section by posting on the Agoyu Terms of Use website, sending you a message, or otherwise notifying you when you are logged into your account. Amendments will become effective thirty (30) days after they are posted on the Agoyu Terms of Use website or sent to you.
Changes to this section will otherwise apply prospectively only to claims arising after the thirtieth (30th) day. If a court or arbitrator decides that this subsection on "Changes to This Section" is not enforceable or valid, then this subsection shall be severed from the section entitled "Arbitration and Class Action Waiver," and the court or arbitrator shall apply the first Arbitration and Class Action Waiver section in existence after you began using the Platform.
Survival: This Arbitration and Class Action Waiver section shall survive any termination of your Account or the Platform.
The Terms and the relationship between you and Agoyu shall be governed in all respects by the laws of the Commonwealth of Virginia, without regard to its conflict of law provisions. You agree that any claim or dispute you may have against Agoyu that is not subject to arbitration must be resolved by a court located in Fairfax County, Virginia, or the United States District Court, Eastern District of Virginia, located in Alexandria, Virginia, except as otherwise agreed by the parties. You agree to submit to the personal jurisdiction of the courts located within Fairfax County, Virginia, or a United States District Court, Eastern District of Virginia, located in Alexandria, Virginia, for the purpose of litigating all such claims or disputes that are not subject to arbitration. You hereby waive any and all jurisdictional and venue defenses otherwise available.
You acknowledge and agree that, to the maximum extent permitted by law, the entire risk arising out of your access to and use of the platform and collective content, your offering or providing moving services or requesting or receiving moving services through the platform, and any contact you have with other users of agoyu or third parties, whether in person or online, remains with you. Neither agoyu nor any other party involved in creating, producing, or delivering the platform will be liable (whether based on warranty, contract, tort (including negligence), product liability or any other legal theory, and whether or not agoyu has been informed of the possibility of such damage, even if a limited remedy set forth herein is found to have failed of its essential purpose) for: (a) any incidental, special, exemplary or consequential damages, including lost profits, loss of data or loss of goodwill, or punitive damages; (b) service interruption, computer damage or system failure; (c) the cost of substitute products or services; (d) any damages for personal or bodily injury or emotional distress arising out of or in connection with these terms; (e) the use of or inability to use the platform, moving services or collective content; (f) any communications, interactions or meetings with other users of the platform or other persons with whom you communicate or interact as a result of your use of the platform; (g) your offering or providing moving services or requesting or receiving moving services through the platform; (h) the loss of any goods, possessions, property, or otherwise; or (I) damage to any property, real or personal.
In no event shall the total, aggregate liability of agoyu and its affiliates and subsidiaries, and their respective officers, directors, employees and agents, arising from or relating to the terms, platform, moving services, and/or collective content, or from the use of or inability to use the platform or collective content or in connection with any moving services or interactions with any other users exceed the total amount of fees actually paid to agoyu by you or by a service provider to agoyu in connection with your moving services hereunder, or one hundred u.S. Dollars if no such payments have been made, as applicable. The limitation of liability described above shall apply fully to residents of new jersey.
You agree to release, defend, indemnify, and hold Agoyu and its affiliates and subsidiaries, and their respective officers, directors, employees and agents, harmless from and against any claims, liabilities, damages, losses, and expenses, including without limitation reasonable legal and accounting fees, arising out of or in any way connected with (a) your violation of these Terms; (b) your User Content; (c) your interaction with any User or user; and (d) the request or receipt or offer or provision of Moving Services by you, including but not limited to any injuries, losses, or damages (compensatory, direct, incidental, consequential or otherwise) of any kind arising in connection with such Moving Services.
Notwithstanding the foregoing paragraph, if you are a resident of New Jersey, you only agree to release, defend, indemnify, and hold Agoyu and its affiliates and subsidiaries, and their respective officers, directors, employees and agents, harmless from and against any third-party claims, liabilities, damages, losses, and expenses, including without limitation reasonable legal and accounting fees, arising out of or in any way connected with your violation of these Terms.
If you are a California resident, you waive California Civil Code Section 1542, which provides:
A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.
If you are not a California resident, you waive your rights under any statute or common law principle similar to Section 1542 that governs your rights in the jurisdiction of your residence.
Agoyu reserves the right, in its sole discretion, to modify these Terms, and any other documents incorporated by reference herein, at any time and without prior notice. Agoyu will notify you of changes by posting on the Agoyu Terms of Use website, sending you a message, and/or otherwise notifying you when you are logged into your account. Modifications will become effective thirty (30) days after the earliest of: (a) modifications being posted on the Platform; (b) Agoyu's transmission of a message to you about the modifications; or (c) you are otherwise notified when you are logged into your account. Your use of the Platform after the expiration of the thirty (30) days shall constitute your consent to the changes. If you do not agree, you may not access or use the Platform. Agoyu may terminate this Agreement at any time upon a notice posted to the Platform's website.
Force Majeure: Other than payment obligations, neither Agoyu nor you shall be liable to the other for any delay or failure in performance under the Terms arising out of a cause beyond its control and without its fault or negligence. Such causes may include but are not limited to fires, floods, earthquakes, strikes, unavailability of necessary utilities, pandemics, blackouts, acts of God, acts of declared or undeclared war, acts of regulatory agencies, or national disasters.
Due Diligence: You acknowledge and agree that you have been advised that you are solely responsible for selection of the Service Provider and for any decision to engage or not to engage with a Service Provider. You have also been advised to request the Service Provider's proof of insurance. You also acknowledge and agree that you may be able to obtain better rates and terms through other sources. You are also responsible for ensuring that the estimate is based upon accurate information and you agree to only provide accurate information through the Platform and to work in good-faith with the Service Providers to improve the accuracy of any estimates provided. You also agree that you have been advised to ask the Service Providers for references and to research online reviews for the Service Providers.
No Third-Party Beneficiaries: You agree that, except as otherwise expressly provided in these Terms, there shall be no third-party beneficiaries to these Terms.
Contacting You and E-SIGN Consent: You agree that Agoyu may provide you with notices, including those regarding changes to the Terms, by email, regular mail, or postings on the Platform. With your consent, Agoyu, Consumer Users, Service Users, or other individuals may also contact you by telephone or through text messages. If you have agreed to receive text messages or telephone calls from Agoyu, Consumer Users, Service Users, or other individuals you also consent to the use of an electronic record to document your agreement. You may withdraw your consent to the use of the electronic record by sending an email to [email protected] with "Revoke Electronic Consent" in the subject line. To view and retain a copy of this disclosure or any information regarding your enrollment in this program, you will need (a) a device (such as a computer or mobile phone) with a web browser and Internet access; and (b) either a printer or storage space on such device. For a free paper copy, or to update our records of your contact information, send an email to [email protected] with contact information and the address for delivery.
Assignment: You will not assign any of your rights or delegate any of your obligations under these Terms without our prior written consent. Any purported assignment or delegation in violation of this provision is null and void. No assignment or delegation relieves you of any of your obligations under these Terms.
Severability: If any provision of these Terms is invalid, illegal, void or unenforceable, then that provision will be deemed severed from these Terms and will not affect the validity or enforceability of the remaining provisions of these Terms.
Entire Agreement: These Terms, together with the Privacy Policy and any other legal notices or additional terms and conditions or policies published by Agoyu on the Platform, shall constitute the entire agreement between you and Agoyu concerning the Platform or Moving Services obtained through the Platform. Except as explicitly stated herein, if any provision of the Terms is deemed invalid by a court of competent jurisdiction, the invalidity of such provision shall not affect the validity of the remaining provisions of the Terms, which shall remain in full force and effect.
Waiver: No waiver of any provision of these Terms shall be deemed a further or continuing waiver of such term or any other term, and Agoyu's failure to assert any right or provision under these Terms shall not constitute a waiver of such right or provision.
Statute of Limitations: You agree that regardless of any statute or law to the contrary, any claim arising out of or related to the Platform or the Moving Services offered therein must commence within one (1) year after the cause of action accrues. Otherwise, such cause of action is permanently barred. Notwithstanding the foregoing, this statute of limitations shall not apply to residents of New Jersey.
Section Headings: The section headings in these Terms are for convenience only and have no legal or contractual effect.


text:
CPHI Online is the largest global marketplace in the pharma ingredients industry
Biopharma News
Biopharma news
News SGS expands testing capabilities at its Glasgow facilityClients will benefit from a fully comprehensive range of validated biosafety methods to support cell bank and viral vaccine manufacturing and lot release of drug product.
News TC BioPharm creates allogeneic cell banks for CAR-T cancer therapy productsThe first completed bio-banks will be used to develop more cost-effective, safe and efficacious cancer treatments.
News Alvotech completes US $300 million financing dealFuels growth and biosimilar development in a fast-growing market.
News Sartorius introduces BIOSTAT RM TX single-use bioreactorFlexsafe RM TX bags enable reliable process performance for optimal cell growth.
News Univercells introduces breakthrough vaccine manufacturing platformThe automated NevoLine bioproduction system that facilitates safer, faster and closed bioprocessing in a much smaller footprint.
News Allergan to establish R&D presence in Cambridge, MassachusettsThe new, strategic presence will allow the company to more easily interact and engage with venture firms and start ups in the area.
News Expedeon signs supply and license agreement for is Lightning-Link technologyThe technology will enable Cell Guidance Systems to manufacture TRIFic detection assays on-demand with highly reproducible and scalable results.
News BMS and Celgene merge to create premier innovative biopharma companySignificantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.
News Pall opens Center of Excellence in ShanghaiThe CoE showcases the latest end-to-end technological solutions for biomanufacturing.
News New gene therapy manufacturing facility for Orchard TherapeuticsEnhances company's capacity to develop and deliver lentiviral vector and gene-corrected hematopoetic stem cells for wide range of diseases on a global scale.
News Grant winners to investigate continuous manufacturing for gene therapiesCobra Biologics, Pall, and the Cell and Gene Therapy Catapult share £1.5 million grant from the UK's innovation agency.
News ADC Bio secures additional equity round investmentExtra funding for strategic move into downstream formulation and fill finish capabilities and full exploitation of Lock-Release as new ADC manufacturing paradigm.
News SSB and Lonza modify relationship for supply of cell culture mediaSartorius Stedim Biotech will continue to offer Lonza media and buffer products but under a non-exclusive agreement.
News bioLIVE to merge with BioProduction Congress for 2019 eventBioProduction's content platform will be added to the bioLIVE exhibition, creating one of the world's largest event hubs for the bio industry.
News Sandoz pulls the plug on US biosimilar rituximabCompany will focus on robust biosimilar portfolio for unmet access and sustainability needs.
News Three-way collaboration to advance gene therapyPartnership aims to increase the robustness and reduce costs for the manufacturing of AAV vectors.
News Bioconjugation expertise and increased productivity in bio over next 5 yearsSmaller bioreactors and high-density perfusion techniques needed as manufacturing makes significant efficiency improvements.
News Alvotech receives manufacturing licence for its biopharmaceutical facilityFacility to focus on developing and manufacturing the company's biosimilar portfolio.
News Complete product lifecycle management in one locationLonza expansion includes drug substance development, and drug substance and drug product manufacturing.
News BIA Separations expands with new upstream processing facilityProvides single source of expertise for scaled production of complex biologics for gene therapy and vaccines.
News Partnership to deliver integrated, off-the-shelf biosimilar manufacturing solutionsPall and Aetos to advance the market impact of biosimilars and deliver lower-priced, high-quality options to end users.
News Aptar Pharma to showcase an industry firstPureHale is a new portable drug delivery device designed for upper respiratory care.
News New SGS biopharmaceutical testing capabilities in IllinoisThe new services will focus on quality control analysis and stability testing of biopharmaceuticals.
News Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolioThe Sandoz US portfolios to be sold to Aurobindo include approximately 300 products, as well as additional development projects.
News Sartorius and Repligen partner to introduce next-generation perfusion-enabled bioreactorsCustomers to benefit from simplified, scalable solutions for intensified cell culture.
News Plasticell wins military contract to develop regenerative medicines for the battlefieldCompany to use its combinatorial stem cell screening platform to develop technologies for the conversion of pluripotent stem cells into platelets.
News Bio processing and manufacturing league table ranks US top and China bottomUS, Germany and Japan revealed as tier one nations in all categories with Sweden ranking the best of the rest.
News New biopharmaceutical testing laboratory to open in GenevaSGS's expansion will enable the service provider to offer a full ICH Q6B physico-chemical characterization of biological products.
News Exosome isolation manufacturing and characterizationNew service to reliably and reproducibly isolate exosomes from almost any biofluid.
News Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell linesCompany moves away from manual processing in favour of automated, scalable platforms.
News Extended distribution agreement enables customers to continuously improve their bioprocessesAgreement includes Pall's next-generation Kaneka KanCapA 3G sorbent for the primary capture of mAbs from clarified cell culture.
News Amgen breaks ground on next-generation biomanufacturing plant in Rhode IslandThe plant will be first-of-its-kind in the US.
News Partnership struck to aid bio manufacturersPall and BioSciencesCorp unite to provide "total solutions" for today's drug manufacturers.
News WuXi STA and Antengene sign development and manufacturing agreementWuXi STA chosen for its end-to-end CMC platform for new drug development.
News New screening company exploits the latest advances in microfluidics and 3D cultureThe ability to micro size drug-cell interactions will allow pharmaceutical and biotech companies to do 100x more testing for the same money spent as well as increasing productivity.
News South Korea's finished drug market growth driven by genericsFDF launches at CPHI Korea as country set to become regional hub.
News Plasticell leads gene therapy manufacturing consortiumConsortium to develop advanced technologies for the manufacturing of ex vivo gene therapies.
News Ingredients to improve bioprocess manufacturing efficiencyExperts warn bio industry needs to do more to create a sustainable pipeline of talent.
News CellGenix completes first step of facility expansionNext expansion step will increase finished product capacity for recombinant proteins by more than tenfold.
News Extended co-operation agreement to benefit Sartorius customersAgreement will enable customers to achieve easier scalability of processes ranging from lab-scale to commercial-scale production of biopharmaceuticals.
News Thermo invests $50 million to enhance biologics capabilitiesWith the capacity expansion, Thermo Fisher will have the second largest base of single-use bioproduction capacity at a CDMO in the world.
News Cost-effective, scalable process development of vaccines in cell cultureSartorius Stedim Biotech introduces its mini microcarrier bioreactor for culturing adherent cells.
News Wacker acquisition increases cost-effective pharmaceutical productionThe contract manufacturer strengthens its pharmaceutical-protein business with Dutch acquisition
News Amgen to build first-of-its-kind biomanufacturing plant in the USRevolutionary, innovative plant offers greater flexibility, speed and efficiency.
News JXTGE to sell Irvine Scientific to FujiFilmWith the acquisition of Irvine Scientific, FujiFilm will have a full product line supporting customers supplying antibody drugs to assisted reproductive technologies and cell therapy.
News bioLIVE to introduce global biopharma country rankingGlobal analysis will rank each major biomanufacturing country's market growth potential, innovation and competitiveness.
News Top marks for Cherwell's Redipor prepared microbial media productsExtensive range of ready-to-use culture media available in bottles and plates.
News ProJect Pharmaceutics expands facilities for formulation and lyophilization process developmentExpansions to meet safety requirements for GMO S2 and BSL-2 biological products.
News Revolutionary downstream bioconjugation method under developmentNew manufacturing paradigm will save 25% of total costs and the need for proteinaceous A & G resins.
News A powerful new tool for the separation of charged speciesA new analytical tool, Electrical Asymmetrical Flow Field-Flow Fractionation (EAF4) is showing much promise in biopharmaceutical and nanoparticle applications.
News New Pall business unit launches to focus on end-to-end drug manufacturing modelsPall Biotech to focus on enabling drug manufacturers to rapidly transition from pre-clinical to commercial manufacturing.
News Ablynx - Sanofi's new acquisitionStrengthens Sanofi's R&D strategy with innovative Nanobody technology platform.
News Sandoz and Biocon to collaborate on next-generation biosimilarsCollaboration will leverage combined strengths of development, manufacturing and commercialization of biosimilars.
News SSB to equip Abzena's US-based development and manufacturing sitesSSB will provide both facilities with end-to-end process solutions in single-use format.
News Momenta and Mylan to development proposed biosimilar to EyleaTargeting the initiation of a pivotal patient clinical trial in the first half of 2018.
News ANVISA approves Biocon and Mylan's biosimilar TrastuzumabLibbs will commercialize the product in Brazil under the brand name Zedora.
News Major changes for bio supply forecast in 2018 by bioLIVEIntegration of supply chain a critical issue as industry globalises, with a resurgence in European manufacturing and biotech markets forecast.
News Hikma signs licensing agreement with Celltrion for third biosimilar product in MENA regionTruxima is mAb biosimilar to Roche's MabThera (rituximab).
News CMC Biologics and Harpoon Therapeutics collaborate on exciting new TriTAC moleculesFirst clinical candidate, HPN424, is in development for the treatment of metastatic prostate cancer and expected to enter Phase I clinical trials in 2018.
News SGS introduces GMP DNA sequencing service at its Glasgow, UK, laboratoryService complements existing services for this testing, to provide comprehensive analysis and characterization solutions for clients involved in the production and manufacturing of biopharmaceutical products.
News SGS launches new large molecule bioanalytical servicesInvestment builds on company's expertise in small molecule analysis and the use of LC/MS-MS techniques.
News Expansion of CSL Biotech facility drives advanced manufacturing growthThe development will help meet growing global demand for albumin.
News Global ADC Bio clients to benefit from new dedicated bioconjugation facilityThe design, planning and building work commences immediately and will deliver a purpose-built, dual-stream facility.
News New clarification platform delivers robust, accelerated performance across multiple mAb processesThe Stax mAx, a single-use harvesting platform, minimizes the impact of process variability between batches.
News Poor aggregation will see ADC targets fail or face long delaysExperts at ADC Bio warn of impending problems in the ADC pipeline with millions wasted in development costs.
News Celonic acquires Glycotope's biomanufacturing facilityCombined technology assets will provides pharmaceutical and biotech customers the unique opportunity to select a tailored expression system.
News Eurofins creates one of the largest dedicated testing sites of its kind in the UK£4 million investment will allow the Biopharmaceutical Product Testing business to expand its finished product and raw materials testing and increase capacity to deal with higher volumes.
News New dedicated biopharma event launches alongside CPHI Worldwide 2018 in MadridNew event to create unique synergies between the parallel worlds of large, small molecules and contract services.
News Batavia expands its viral vector and cleanroom facilities to stay on top of demandInvestments will help the company to bring candidate biopharmaceuticals from bench to clinic.
News Construction starts for Sartorius' new Cell Culture Technology CentreThe 30-million-euro investment will accommodate the growing needs of customers.
News PnuVax awarded $29.4 million grant to advance innovative vaccine into clinical trialsUse of PnuVax's unique patented conjugation platform technology to produce the vaccine is expected to speed up biomanufacturing and increase yield for a greatly reduced per-dose cost.
News 3SBio accelerates expansion of its global biologics platformThe Chinese biopharmaceutical company acquires the Canadian biomanufacturing business of Therapure.
News Bayer submits BLA in the for BAY94-9027 – a long-acting factor VIII for the treatment of hemophilia APivotal studies with BAY94-9027 showed that bleed protection was achieved with extended dosing intervals.
News Merck successfully closes biosimilars transactionStep towards strategic alignment of R&D resources to Healthcare priorities.
News Biogen's adalimumab biosimilar referencing Humira, is approved in the EUBiogen becomes the first company with approved biosimilars for the three most prescribed anti-TNF biologic treatments in Europe.
News Boehringer Ingelheim receives FDA approval for its Humira biosimilarCyltezo approved for the treatment of multiple chronic inflammatory diseases.
News Biopharma stages a strong recovery over the first half even as M&A deals disappointEP Vantage releases half-year reviews of pharma & biotech and medtech performance.
News Amgen submits sBLA for Prolia in glucocorticoid-induced osteoporosisResults from the Phase III study included in the sBLA submission showed that treatment with Prolia for 12 months led to statistically significant greater gains in BMD at the lumbar spine and total hip compared to risedronate.
News Boehringer starts clinical study on interchangeability between adalimumab biosimilar candidate and US-formulated HumiraFirst study in the US to investigate an interchangeability designation for an adalimumab biosimilar candidate.
News Pall introduces proprietary bioreactor control systemThe mPath bioreactor control system is the first to be developed and delivered by a technology supplier specifically for their product line, allowing full access to bioreactor capabilities that current commercial solutions cannot provide.
News Valeant launches Siliq Injection in USDermatology unit is rebranded Ortho Dermatologics.
News Merck launches Remicade biosimilar for all eligible indications, in the USThe biosimilar's list price will represent a 35% discount to the current list price of Remicade.
News Lilly backs Nektar Therapeutics' novel immunological therapyNKTR-358 has the potential to treat a number of autoimmune and other chronic inflammatory conditions.
News GSK delivers double-edged swordCompany announces investments, the sale of several products and a proposal to close a UK manufacturing site.
News FDA committee recommends approval of Mylan and Biocon's proposed biosimilar trastuzumabVote marks first proposed biosimilar trastuzumab to be recommended by the committee.
News FDA approves Blincyto to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemiaBlincyto is the first and only Bispecific T cell Engager (BiTE) immunotherapy to demonstrate superior overall survival versus standard of care chemotherapy.
News Sanofi to acquire Protein SciencesAcquisition adds recombinant-based influenza vaccine to Sanofi Pasteur's portfolio.
News BIOCAD's rituximab biosimilar to receive MA in IndiaFirst shipment of BIOCAD's Acellbia to India is scheduled for September 2017.
News FDA approves Vectibix for use in wild-type RAS metastatic colorectal cancerFirst-and-only fully human monoclonal anti-epidermal growth factor receptor antibody approved by the FDA for this patient population.
News Biogen's Imraldi, an adalimumab biosimilar candidate referencing Humira, granted positive opinion by CHMPIf approved, Imraldi will be the third anti-TNF biosimilar in Biogen's portfolio in Europe.
News FDA accepts Amgen's sBLA to expand indication for Xgeva to include multiple myeloma patientsXgeva is indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumours and is the number one prescribed agent by oncologists for this indication in the US.
News Sandoz receives approval in Europe for Rixathon to treat blood cancers and immunological diseasesSandoz now has four biosimilars approved in Europe - more than any other company.
News FDA Advisory Committee to review Avastin biosimilar candidateThe Committee will review analytical, pharmacokinetic and clinical data from studies involving ABP 215, including results from a Phase III study in patients with NSCLC.
News Sartorius Stedim Biotech launches ambr 15 bioreactor system with Nova BioProfile FLEX2 integrationQbD studies in upstream processing more rapidly performed.
News Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the EMABiosimilar infliximab alone could potentially save the NHS £89 million.
News Boehringer Ingelheim inaugurates biopharmaceutical manufacturing facility in ChinaIt is the first and only biopharmaceutical manufacturing site established by a multinational active pharmaceutical company in China.
News Irvine Scientific launches new xeno-free medium for hematopoietic progenitor cell cultureNew medium designed for hematopoietic cell culture for cell-based therapies.
News Sartorius Stedim Biotech partners with Nova BiomedicalUnique tool will allow massive quantities of cell culture data to be collected during upstream processing QbD studies.
News Merck launches industry's first off-the-shelf cell culture media for perfusion processesAllows customers to achieve a more optimal output than they would using conventional batch or fed-batch processes.
News Sartorius Stedim Biotech launches chemistry testing servicesThis chemistry testing offer complements the company's existing range of off-the-shelf biological assays for biosimilar products, providing a complete solution from one contract partner.
News GSK invests $139 million to expand production capacity for Benlysta in RockvilleSite is also expected to house production of a new subcutaneous form of belimumab, which is currently under review with the FDA.
News Sartorius introduces new BIOSTAT STR bioreactor range and new Flexsafe STR single-use bagsNew generation of bioreactors combined with new Flexsafe STR bags offer a fully scalable, single-use system.
News Fresenius Kabi to strengthen and diversify product portfolio by acquiring Akorn and Merck KGaA's biosimilars businessTransactions provide access to attractive pharmaceutical growth markets.
News Sandoz proposed biosimilars rituximab and etanercept recommended for approval in EuropeCompany receives positive CHMP opinions for biosimilars rituximab and etanercept to treat immunological diseases. Biosimilar rituximab also recommended to treat blood cancers.
News Fujifilm increases production capacity and establishes new process development facilities$130M USD investment to support growing market demand.
News Millipore Express high area filters ideal for processing feed streams with high particulate levelsGreater filtration capacity with a smaller footprint than conventional filters, improving economics for biopharmaceutical manufacturing.
News Amgen submits applications in the US and Europe to expand current indication for XgevaApplications include data from the largest international trial conducted in multiple myeloma.
News Analytical protein aggregate separation without a columnSystem can achieve separations with higher resolution, reproducibility and recovery then has previously been possible.
News $100 billion of revenues up for grabs for drug manufacturers as patents for key biologics expireFor success in the biosimilars sector, manufacturers must adopt QbD, DoE and PAT initiatives.
News Proclara Biosciences Australia awarded grant to help develop new biotherapy with blockbuster potentialWork on a second-generation fusion protein due to start in 2017 at Patheon's manufacturing facility in Brisbane.
News Horizon Discovery enters into R&D and licensing partnership for bioproduction cell line optimisationPartnership formed to evaluate the impact of Amplycell's novel cell fitness technology on expression capacity of Horizon's bioproduction cell line.
News Apotex to invest $184 million to grow US manufacturing presenceExpansion plan comprises company's largest investment in the US.
News Sandoz proposed biosimilar adalimumab demonstrates equivalent efficacy as HumiraComprehensive development program show potential of GP2017 to treat inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis.
News First ever biosimilar of interferon beta-1a approved in RussiaRepresents Biocad's third authorized medicine for the treatment of relapsing-remitting multiple sclerosis.
News Allergopharma opens new biopharmaceutical production in ReinbekMerck's €42 million investment expands the allergies business on a global scale.
News Sanofi Pasteur and MedImmune collaborate on monoclonal antibody to prevent illnesses associated with RSVMEDI8897 has been engineered to have a long half-life so that only one dose would be needed for the entire RSV season.
News Roquette commits to bioharma market with new productsReinforces position as a supplier of excipients and raw materials for the pharmaceutical and biopharmaceutical industries.
News FDA accepts BLA for avelumab for the treatment of metastatic urothelial carcinoma for Priority ReviewSecond Biologics License Application accepted by the FDA for avelumab.
News Sanofi and Lonza join hands to establish large-scale biologics production facilityPartnership leverages Lonza's expertise in large-scale mammalian cell culture facilities alongside Sanofi's strength in developing and launching biologics based treatments.
News Valeant's treatment for plaque psoriasis gets FDA thumbs up for SiliqMore than 50% of patients in three clinical studies who used Siliq achieved total skin clearance within a year.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
Generate high-quality, engaged leads for your business, all year round
Promote your business as the industry's thought-leader by hosting your reports, brochures and videos within your profile
Your company's profile boosted at all participating CPHI events
An easy-to-use platform with a detailed dashboard showing your leads and performance


text:
Capital Markets
Capital Markets
- Learn More
Our lawyers provide innovative and practical counsel on a wide variety of capital raising and securities law compliance matters. We represent clients ranging from emerging private companies to established public companies. With each, we build long-term relationships, generating efficiencies and helping them realize their business goals.
Algoma Steel Repurchases $400 Million in Shares Via Self-Tender Offer
- Client News
- August 2, 2022
Paul, Weiss advised Algoma Steel Group Inc. in its self-tender offer to repurchase $400 million of its common shares at a price of $9.75 per share. The offer proceeded by way of a modified Dutch auction within a range of $8.75 to $10.25 per share, and was oversubscribed. BMO Nesbitt Burns Inc. and BMO Capital Markets Corp. acted as dealer managers in connection with the offer in Canada and the United States, respectively, and as financial advisors to Algoma.
Based in Sault Ste. Marie, Ontario, Algoma is a fully integrated producer of hot and cold rolled steel products including sheet and plate. Algoma is a key supplier of steel products to customers in Canada and the Midwest United States, and is the only producer of plate steel products in Canada.
The Paul, Weiss team included corporate partners Christopher Cummings and Adam Givertz and counsel Christian Kurtz; and tax partner Brian Grieve and counsel Sohail Itani.